Company intelligence / Profile preview
MUVON Therapeutics
Zurich, Switzerlandmuvon-therapeutics.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Successfully completed Phase I clinical trial for stress urinary incontinence treatment, showing functional restoration of the sphincter muscle in patients. Currently conducting Phase II clinical study (SUISSE MPC 2-Study) with first patient enrolled as of October 27, 2022[7][9].
- Therapeutic areas
- RheumatologyWomen's Health
- Modalities
- Cell therapyAutologous cell therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
admedicum GmbH & Co KG[7]
Beyond the preview
Go deeper on MUVON Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MUVON Therapeutics.